BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Safiglipron (HRS-7535) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Safiglipron (HRS-7535)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06820099-186@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Safiglipron (HRS-7535): Phase 2 readout est. (NCT06820099)
DESCRIPTION:Safiglipron (HRS-7535)\, phase 2\, Obesity.\nStudy: Study on th
 e Efficacy and Safety of HRS-7535 in Patients With Mild Decrease in Ejecti
 on Fraction/Preserved Ejection Fraction Heart Failure and Obesity\nEstimat
 ed primary completion: December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/safiglipron-hrs-7535#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06820099
URL:https://assetmemo.bio/drug/safiglipron-hrs-7535#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07497880-186@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20270707
DTEND;VALUE=DATE:20270708
SUMMARY:Safiglipron (HRS-7535): Phase 2 readout est. (NCT07497880)
DESCRIPTION:Safiglipron (HRS-7535)\, phase 2\, Obesity.\nStudy: Efficacy an
 d Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Ove
 rweight With at Least 1 Weight-Related Comorbidity\nEstimated primary comp
 letion: 7 July 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 safiglipron-hrs-7535#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07497880
URL:https://assetmemo.bio/drug/safiglipron-hrs-7535#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07528027-186@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Safiglipron (HRS-7535): Phase 3 readout est. (NCT07528027)
DESCRIPTION:Safiglipron (HRS-7535)\, phase 3\, Obesity.\nStudy: Phase III S
 tudy of HRS-7535 for Hypertension With Overweight or Obesity\nEstimated pr
 imary completion: December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/safiglipron-hrs-7535#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07528027
URL:https://assetmemo.bio/drug/safiglipron-hrs-7535#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07625774-186@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20310531
DTEND;VALUE=DATE:20310601
SUMMARY:Safiglipron (HRS-7535): Phase 3 readout est. (NCT07625774)
DESCRIPTION:Safiglipron (HRS-7535)\, phase 3\, Chronic Kidney Disease.\nStu
 dy: Renal Efficacy and Safety of the Novel Oral Small-Molecule GLP-1RA HRS
 -7535 Evaluated in Participants With Chronic Kidney Disease\nEstimated pri
 mary completion: May 2031. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/safiglipron-hrs-7535#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07625774
URL:https://assetmemo.bio/drug/safiglipron-hrs-7535#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
